目的 探析金水宝片联合达格列净治疗糖尿病肾病的效果。方法 收集2022年1月—2024年2月在中国人民解放军联勤保障部队第九〇四医院接受治疗的102例糖尿病肾病患者资料，按治疗方式将患者分为对照组和治疗组，每组各51例。对照组患者口服达格列净片，1片/次，1次/d；治疗组患者在对照组基础上口服金水宝片，4片/次，3次/d。两组均连续治疗12周。比较两组临床疗效、血糖指标、血管内皮指标和肾功能指标。结果 治疗组的总有效率96.08%高于对照组的总有效率84.31%（P＜0.05）。与治疗前相比，两组空腹血糖、糖化血红蛋白（HbA1c）均降低（P＜0.05），且治疗组各血糖指标水平较对照组均更低（P＜0.05）。与治疗前相比，两组患者血清一氧化氮（NO）水平升高，血清内皮素-1（ET-1）水平降低（P＜0.05），且治疗组较对照组血清NO水平更高，血清ET-1水平更低（P＜0.05）。与治疗前相比，两组患者血清血肌酐（Scr）、血尿素氮（BUN）均降低（P＜0.05），且治疗组肾功能指标水平较对照组更低（P＜0.05）。结论 金水宝片联合达格列净治疗糖尿病肾病可控制患者血糖，改善肾功能，保护血管内皮功能。

Objective To explore the effect of Jinshuibao Tablets combined with dapagliflozin in treatment of diabetes nephropathy. Methods The data of 102 patients with diabetes nephropathy who were treated in the 94th Hospital of the Joint Logistic Support Force of PLA from January 2022 to February 2024 were collected. The patients were divided into control and treatment group according to the treatment mode, with 51cases in each group. The control group patients took Dapagliflozin tablets orally, 1 tablets/time, once daily. On the basis of the control group, the treatment group took Jinshuibao Tablets orally, 4 tablets/time, 3 times daily. Both groups were treated continuously for 12 weeks. The clinical efficacy, blood glucose indicators, vascular endothelial indicators, and renal function indicators between two groups were compared. Results The total effective rate (96.08%) of the treatment group was higher than 84.31% of the control group (P < 0.05). After treatment, fasting blood glucose and HbA1c levels in two groups were decreased (P < 0.05), and the various blood glucose indicators levels in the treatment group were lower than those in the control group (P < 0.05). Compared with before treatment, both groups showed an increase in serum NO and a decrease in serum ET-1 levels (P < 0.05). And the treatment group had higher serum NO levels and lower serum ET-1 levels than those in the control group (P < 0.05). The serum levels of Scr and BUN in both groups were decreased after treatment (P < 0.05), and the serum levels of Scr and BUN in the treatment group were lower than those in the control group (P < 0.05). Conclusion Jinshuibao Tablets combined with dapagliflozin is effective in treatment of diabetes nephropathy, and can control blood sugar, improve renal function and protect vascular endothelial function.

R977

苏州市“科教兴卫”青年科技项目（KJXW2022086）